David Van Echo

1.1k total citations
24 papers, 884 citations indexed

About

David Van Echo is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, David Van Echo has authored 24 papers receiving a total of 884 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 7 papers in Molecular Biology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in David Van Echo's work include Cancer Treatment and Pharmacology (5 papers), Hepatocellular Carcinoma Treatment and Prognosis (3 papers) and Pancreatic and Hepatic Oncology Research (3 papers). David Van Echo is often cited by papers focused on Cancer Treatment and Pharmacology (5 papers), Hepatocellular Carcinoma Treatment and Prognosis (3 papers) and Pancreatic and Hepatic Oncology Research (3 papers). David Van Echo collaborates with scholars based in United States, New Zealand and Japan. David Van Echo's co-authors include George E. Peoples, Erika J Schneble, Jarrod P. Holmes, Guy T. Clifton, Sathibalan Ponniah, EA Mittendorf, Mario A. Eisenberger, Ross C. Donehower, Monica B. Spaulding and Javier Hornedo and has published in prestigious journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and Annals of Oncology.

In The Last Decade

David Van Echo

24 papers receiving 865 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Van Echo United States 12 361 256 228 146 124 24 884
Andréia Cristina de Melo Brazil 20 583 1.6× 120 0.5× 342 1.5× 92 0.6× 170 1.4× 143 1.3k
T. Reid United States 18 472 1.3× 122 0.5× 539 2.4× 115 0.8× 101 0.8× 53 1.4k
Sophie Papa United Kingdom 23 952 2.6× 360 1.4× 281 1.2× 102 0.7× 287 2.3× 57 1.8k
Wenjun Cao China 20 147 0.4× 50 0.2× 256 1.1× 88 0.6× 67 0.5× 70 1.0k
Roopa Hariprasad India 16 291 0.8× 37 0.1× 178 0.8× 83 0.6× 43 0.3× 78 968
Jane Wu United States 13 545 1.5× 147 0.6× 235 1.0× 41 0.3× 314 2.5× 33 1.3k
Praveen Vikas United States 13 551 1.5× 117 0.5× 263 1.2× 110 0.8× 139 1.1× 27 988
Sharmila Pimple India 14 259 0.7× 50 0.2× 161 0.7× 72 0.5× 24 0.2× 49 1.1k
Ruth Sepper Estonia 17 153 0.4× 98 0.4× 189 0.8× 91 0.6× 426 3.4× 30 1.1k
Zahra Mojtahedi Iran 20 201 0.6× 229 0.9× 371 1.6× 101 0.7× 68 0.5× 71 859

Countries citing papers authored by David Van Echo

Since Specialization
Citations

This map shows the geographic impact of David Van Echo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Van Echo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Van Echo more than expected).

Fields of papers citing papers by David Van Echo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Van Echo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Van Echo. The network helps show where David Van Echo may publish in the future.

Co-authorship network of co-authors of David Van Echo

This figure shows the co-authorship network connecting the top 25 collaborators of David Van Echo. A scholar is included among the top collaborators of David Van Echo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Van Echo. David Van Echo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Johnson, William R., Brett Theeler, David Van Echo, Patrick Young, & Mary Kwok. (2018). Treatment of Leptomeningeal Carcinomatosis in a Patient with Metastatic Pancreatic Cancer: A Case Report and Review of the Literature. Case Reports in Oncology. 11(2). 281–288. 10 indexed citations
2.
Mittendorf, EA, Guy T. Clifton, Jarrod P. Holmes, et al.. (2014). Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients. Annals of Oncology. 25(9). 1735–1742. 189 indexed citations
3.
Ake, Julie A., Paul T. Scott, Glenn Wortmann, et al.. (2011). Gram-Negative Multidrug-Resistant Organism Colonization in a US Military Healthcare Facility in Iraq. Infection Control and Hospital Epidemiology. 32(6). 545–552. 26 indexed citations
4.
Tkaczuk, Katherine H. R., Nancy Tait, Olga B. Ioffe, et al.. (2011). Computer assisted quantitative immunofluorescence of tumor tissue marker expression and clinical outcome to chemotherapy in advanced breast cancer patients.. PubMed. 12(62). 33–40. 3 indexed citations
5.
6.
Roberts, Zachary, Nadège Goutagny, Pin‐Yu Perera, et al.. (2007). The chemotherapeutic agent DMXAA potently and specifically activates the TBK1–IRF-3 signaling axis. The Journal of Experimental Medicine. 204(7). 1559–1569. 127 indexed citations
7.
Nemunaitis, John, Gary L. Clayman, John Hamm, et al.. (2007). Tumor response criteria and biomarkers associated with increased survival following adenoviral p53 gene therapy (ADVEXIN) in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN). Journal of Clinical Oncology. 25(18_suppl). 6057–6057. 3 indexed citations
8.
9.
Edelman, Martin J., Kenneth S. Bauer, Nancy Tait, et al.. (2003). Clinical and pharmacologic study of tributyrin: an oral butyrate prodrug. Cancer Chemotherapy and Pharmacology. 51(5). 439–444. 72 indexed citations
10.
Meropol, Neal J., Kevin P. Weinfurt, Caroline B. Burnett, et al.. (2003). Perceptions of Patients and Physicians Regarding Phase I Cancer Clinical Trials: Implications for Physician-Patient Communication. Journal of Clinical Oncology. 21(13). 2589–2596. 171 indexed citations
11.
Kennedy, Andrew S., et al.. (2001). Preliminary results of outpatient hepatic artery brachytherapy for colorectal hepatic metastases. European Journal of Cancer. 37. S289–S290. 4 indexed citations
12.
Johnson, Lynt B., Thorsten Krebs, David Van Echo, et al.. (1997). Cytoablative therapy with combined resection and cryosurgery for limited bilobar hepatic colorectal metastases. The American Journal of Surgery. 174(6). 610–613. 24 indexed citations
13.
Echo, David Van, Ann H. Korzun, I. Craig Henderson, et al.. (1990). Esorubicin (4′-Deoxydoxorubicin, NSC 267469) in Advanced Breast Cancer. American Journal of Clinical Oncology. 13(3). 233–237. 2 indexed citations
14.
Eisenberger, Mario A., Steven H. Krasnow, Susan S. Ellenberg, et al.. (1989). A comparison of carboplatin plus methotrexate versus methotrexate alone in patients with recurrent and metastatic head and neck cancer.. Journal of Clinical Oncology. 7(9). 1341–1345. 31 indexed citations
15.
Belani, Chandra P., et al.. (1987). Phase II study of caracemide in advanced or recurrent non-small cell lung cancer.. PubMed. 71(11). 1099–100. 8 indexed citations
16.
Eisenberger, Mario A., et al.. (1986). Carboplatin (NSC-241-240): an active platinum analog for the treatment of squamous-cell carcinoma of the head and neck.. Journal of Clinical Oncology. 4(10). 1506–1509. 97 indexed citations
17.
Tchekmedyian, N. Simon, Nancy Tait, David Van Echo, & Joseph Aisner. (1986). High-dose chemotherapy without autologous bone marrow transplantation in melanoma.. Journal of Clinical Oncology. 4(12). 1811–1818. 10 indexed citations
18.
Forastiere, Arlene A., Stanley M. Crain, Karen E. Callahan, et al.. (1982). Phase II trial of aziridinylbenzoquinone (AZQ) in head and neck cancer.. PubMed. 66(12). 2097–8. 1 indexed citations
19.
Egorin, Merrill J., et al.. (1982). Plasma kinetics of aclacinomycin A and its major metabolites in man. Cancer Chemotherapy and Pharmacology. 8(1). 41–46. 11 indexed citations
20.
Hoff, Daniel D. Von, et al.. (1982). Phase II evaluation of bisantrene in patients with renal cell carcinoma.. PubMed. 66(10). 1869–71. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Andréia Cristina de Melo Breakdown of academic impact, for papers by T. Reid Breakdown of academic impact, for papers by Sophie Papa Breakdown of academic impact, for papers by Wenjun Cao Breakdown of academic impact, for papers by Roopa Hariprasad Breakdown of academic impact, for papers by Jane Wu Breakdown of academic impact, for papers by Praveen Vikas Breakdown of academic impact, for papers by Sharmila Pimple Breakdown of academic impact, for papers by Ruth Sepper Breakdown of academic impact, for papers by Zahra Mojtahedi
Rankless by CCL
2026